Viva Biotech's Remarkable Annual Performance and Future Prospects
Viva Biotech has recently showcased impressive results for the year ended December 31, 2024. With substantial revenue indicators reflecting a remarkable recovery, the company is poised for an exciting future in drug research and development.
Outstanding Annual Results
The company's revenue hit an impressive RMB1,986.7 million, highlighting its successful turnaround as it also reported a gross profit of RMB687.4 million. Notably, the net profit recorded stood at RMB222.0 million, a staggering improvement from a net loss of RMB99.8 million faced the previous year. This turnaround is largely credited to significant adjustments made within the company, including the full repayment of convertible bonds and the improved operational efficiency.
Strong Non-IFRS Figures
An encouraging element of these results is the adjusted non-IFRS net profit, which reached RMB314.6 million, marking a considerable annual increase of 50.6%. This growth comes as a direct outcome of improving profit margins resulting from rising demand in the Contract Research Organization (CRO) sector.
Strategic Developments and Collaborations
Another highlight is the successful transformation of Viva Biotech Shanghai into a joint stock limited company, now holding approximately 72.9% of total issued share capital. This development empowers the company to leverage strategic investors and bolster its governance and operational capacity.
CRO Revenue Recovery
Despite a slight dip in CRO revenue to RMB810.9 million in 2024, the upward trend becomes apparent in the latter half of the year, reflecting a recovery in the global biopharmaceutical landscape. Furthermore, the order value growth illustrates renewed confidence and increasing demand from customers, establishing a solid foundation for future expansion in 2025.
Innovative AI-Driven R&D
Viva Biotech recognizes the crucial role artificial intelligence (AI) plays in its drug discovery initiatives. This year, exciting features of the R&D landscape were showcased with a reported revenue from AI-enabled projects exceeding US$10 million. The integration of AI technologies is designed to elevate the efficiency and success rates of drug discovery across various developmental stages.
New Drug Discovery Platforms
The establishment of advanced platforms, such as the XDC platform and peptide technology platform, enhances the company's capabilities, ensuring it remains at the forefront of drug development. These innovations allow for comprehensive research and enable the company to cater to various client needs with impressive accuracy and speed.
CDMO Business Expansion
Viva Biotech is steadfast in its mission to construct a robust, one-stop service model for drug R&D and production. With the acquisition of Zhejiang Langhua Pharmaceutical Co., Ltd., they have completed the production phase deployment. This operational pivot will enable them to launch new commercial projects in the upcoming years and enhance overall business efficiency.
Client Relationships and Revenue Streams
Langhua Pharmaceutical reported revenues of RMB1,175.7 million and showcased a 100% retention rate from top clients. The business is set up for further expansion, with new commercialized projects anticipated to contribute significantly to revenue growth.
Investment Returns and Portfolio Growth
Throughout the year, the company successfully realized returns from its investments in various portfolio companies, generating substantial income. Moreover, the proactive financing activities of these companies demonstrate their growth potential, appealing to investors and allowing for further funding rounds.
Future Focus and Strategic Investments
Viva Biotech's strategy encompasses investing in high-quality assets to safeguard future gains. As many portfolio companies show promising progress, the company aims to ensure that these investments mature into fruitful returns. A strategic emphasis on portfolio diversification will play a crucial role in enhancing the Group's financial stability.
Looking Ahead: Growth and Innovation
Dr. Mao Chen Cheney, the Chairman and CEO, expresses a clear commitment to enhancing synergies between their various business sectors. This focus will ensure that Viva Biotech strengthens its offerings, encouraging innovative R&D while establishing itself as a vital player globally in the biopharma space.
Commitment to Quality and Compliance
The company emphasizes its dedication to maintaining high standards across all operations, evidenced by successful inspections from regulatory bodies. These measures assure clients of the quality and safety of the services provided, establishing Viva Biotech as a trustworthy partner in the biopharmaceutical industry.
Frequently Asked Questions
What were Viva Biotech's total revenues in 2024?
The total revenues reached RMB1,986.7 million for the year ended December 31, 2024.
How much did the adjusted non-IFRS net profit increase?
The adjusted non-IFRS net profit increased by nearly 50.6%, totaling RMB314.6 million.
What role does AI play in Viva Biotech's R&D?
AI technologies enhance the efficiency and success rates in the drug discovery process, with revenue from AI projects surpassing US$10 million.
How does Viva Biotech plan to expand its CDMO services?
The company is expanding capacity and launching new commercial projects through its recent acquisition of Langhua Pharmaceutical.
What is the company’s investment strategy regarding portfolio companies?
Viva Biotech aims to focus on high-quality assets, ensuring healthy returns on investments and supporting growth in its portfolio companies.
